|Bid||23.40 x 900|
|Ask||28.30 x 21500|
|Day's Range||27.97 - 28.22|
|52 Week Range||22.70 - 29.93|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 1, 2017 - Nov 6, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||30.00|
Stock Research Monitor: ILMN, NXTM, and SIEN LONDON, UK / ACCESSWIRE / May 22, 2018 / If you want a free Stock Review on VLRX sign up now at www.wallstequities.com/registration . For today, WallStEquities.com ...
NEW YORK, May 08, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The ...
Stock Monitor: Milestone Scientific Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 17, 2018 / Active-Investors.com has just released a free research report on Nxstage Medical, Inc. (NASDAQ: NXTM ...
Innovative AVF needle guard includes enhancements designed to prevent needlesticks LAWRENCE, Mass. , April 13, 2018 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company ...
Company lights Boston's Zakim Bridge and boosts educational awareness efforts on the benefits of home hemodialysis and more frequent therapy. LAWRENCE, Mass., March 15, 2018 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), the manufacturer of the NxStage® System One™ home hemodialysis system, is celebrating the fifth annual Home Hemodialysis (HHD) Day on March 15, 2018. Annually observed during National Kidney Month, this initiative focuses on raising awareness of home hemodialysis and more frequent therapy as a viable treatment option for patients requiring dialysis.
LAWRENCE, Mass., March 13, 2018 /PRNewswire/ -- NxStage Medical, Inc. (NXTM), a leading medical technology company focused on advancing renal care, announced new findings further demonstrating the benefits of home hemodialysis with the NxStage® System One™, including on-site hemodialysis at skilled nursing facilities, solo home hemodialysis, and more frequent home hemodialysis. Eric Weinhandl, PhD, MS, NxStage Clinical Epidemiologist and Adjunct Assistant Professor at the University of Minnesota, presented a study of hospitalization and related Medicare expenditures in the roughly 8,000 nursing home residents per year who initiated dialysis.
Abiomed (ABMD) is strategically focused on the market penetration of the company’s family of Impella heart pumps. The Impella device portfolio consists of Impella 2.5, Impella CP, Impella RP, Impella LD, and Impella 5.0 devices. To this end, Abiomed discontinued the sale of its AB5000 device used for heart surgery.
Abiomed (ABMD) is a supplier of mechanical circulatory support devices and offers a continuum of care to heart failure patients. Abiomed develops, manufactures, and commercializes products designed to improve the blood flow and perform the pumping function of the heart. Of the ten analysts covering Abiomed (ABMD) in February 2018, five analysts have given the stock a “strong buy” rating, three analysts have given it a “buy” rating, while two analysts have given it a “hold” rating.
At present, in-center hemodialysis is the predominant ESRD (end stage renal disease) therapy in the United States. According to NxStage Medical (NXTM), ~10%–15% of ESRD patients in the United States would be appropriate candidates for the company’s home dialysis equipment, System One. According to Centers for Medicare and Medicaid (or CMS), only 18% of dialysis clinics in the United States actively offer home hemodialysis for patients, and only 27% are certified to offer this therapy.
Since its inception, NxStage Medical (NXTM) has focused on creating a long-term sustainable model driven by innovative technologies. Although NxStage Medical has witnessed revenue growth, it has historically operated at a net loss. It expects the operating income it generates from its products business to continue to be offset by the losses in its kidney care business and the costs associated with its merger with Fresenius Medical Care Holdings (FAS).
Headquartered in Lawrence, Massachusetts, NxStage Medical (NXTM) is a medical technology company with a focus on developing, manufacturing, and marketing innovative products targeted at patients suffering from chronic or acute kidney failure. The company also operates NxStage kidney care dialysis centers, which treat end-stage renal disease (or ESRD) patients. NxStage Medical’s primary product is System One, which is capable of delivering the therapeutic flexibility and clinical benefits of traditional dialysis machines in a smaller, portable, and easy-to-use format.
Categories: Yahoo FinanceGet free summary analysis NxStage Medical, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of NxStage Medical, Inc. – Rockwell Medical, Inc., Fresenius Medical Care AG & Co. KGaA Sponsored ADR, Cantel Medical Corp., C. R. Bard, Inc., Baxter International Inc., Nephros, Inc., ... Read more (Read more...)
"The more I realize how things have changed for the better, the more amazed I am," said Maria Jimenez, a former NxStage patient. "Switching from in-center to home hemodialysis with NxStage System One was life-changing for me. Soon after I started dialyzing more often at home, I noticed I felt better and had more energy. I am extremely thankful for everything home hemodialysis has given me, and I know more frequent treatments got me where I am today.